{"id":55637,"date":"2026-01-27T19:47:41","date_gmt":"2026-01-27T11:47:41","guid":{"rendered":"https:\/\/flcube.com\/?p=55637"},"modified":"2026-01-27T19:47:42","modified_gmt":"2026-01-27T11:47:42","slug":"innovent-biologics-secures-fda-fast-track-for-ibi3003-trispecific-antibody-in-multiple-myeloma","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=55637","title":{"rendered":"Innovent Biologics Secures FDA Fast Track for IBI3003 Trispecific Antibody in Multiple Myeloma"},"content":{"rendered":"\n

Innovent Biologics, Inc.<\/strong> (HKG: 1801<\/a>) announced that the U.S. Food and Drug Administration (FDA)<\/strong> has granted Fast Track Designation (FTD)<\/strong> for IBI3003<\/strong>, its anti\u2011GPRC5D\/BCMA\/CD3 trispecific antibody, for the treatment of relapsed or refractory multiple myeloma (R\/R MM)<\/strong> in patients who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory drug, and an anti\u2011CD38 monoclonal antibody.<\/p>\n\n\n\n

Regulatory Milestone & Drug Profile<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Company<\/strong><\/td>Innovent Biologics, Inc. (1801.HK)<\/td><\/tr>
Asset<\/strong><\/td>IBI3003 (anti\u2011GPRC5D\/BCMA\/CD3 trispecific antibody)<\/td><\/tr>
Designation<\/strong><\/td>FDA Fast Track Designation<\/td><\/tr>
Indication<\/strong><\/td>Relapsed\/Refractory Multiple Myeloma (R\/R MM) \u2013 patients with \u22654 prior lines<\/td><\/tr>
Technology<\/strong><\/td>Innovent\u2019s proprietary Sanbody platform<\/td><\/tr>
Mechanism<\/strong><\/td>Simultaneously targets GPRC5D, BCMA, and CD3 to overcome tumor escape<\/td><\/tr>
Clinical Trials<\/strong><\/td>Phase\u202fI\/II (NCT06083207) ongoing in China and Australia; US study approved Dec\u202f2025<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Technology Innovation & Differentiation<\/h2>\n\n\n\n